More than 20% of the global population is affected by eye condition called Allergic conjunctivitis. It is an allergic reaction of the outer lining of the eyeball (conjunctiva) to particles in the environment that act as allergens to certain individuals. Dust, pollen, animal dander, and sometimes even medications are all possible allergens. The eyes become red, watery, and itchy or swollen when exposed to these allergens. Although these symptoms can look like the signs of an infection, allergic conjunctivitis is not infectious or contagious. Allergic conjunctivitis is quite common. It is just the body’s reaction to substances that it considers potentially harmful. There are different types of allergic conjunctivitis such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, giant papillary conjunctivitis, vernal kerato conjunctivitis, and atopic kerato conjunctivitis.
Market Dynamics
Key players operating in the global allergic conjunctivitis market are focusing on adoption of growth strategies such as product launch, regulatory approval, and research and development for the treatment of allergic conjunctivitis, which are expected to drive the market growth during the forecast period. For instance, in March 2020, Eyevance Pharmaceuticals, is a provider of ophthalmic products and therapies intended to address unmet medical needs, announced the U.S. launch of Zerviate (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis. Moreover, in June 2017, Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, announced results from a Phase 2b clinical trial of topical ocular ADX-102 in patients with allergic conjunctivitis.
Key features of the study:
- This report provides in-depth analysis of the Global Allergic Conjunctivitis Market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Global Allergic Conjunctivitis Market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Eton Pharmaceutical, Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Ocular Therapeutix, Inc., Eyevance Pharmaceuticals LLC, Alcon, Santen Pharmaceutical Co., Ltd., Auven Therapeutics, and Atopix Therapeutics Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The Global Allergic Conjunctivitis Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Allergic Conjunctivitis Market.
Detailed Segmentation:
- Global Allergic Conjunctivitis Market, By Drug Class :
- Antihistamines & Mast Cell Stabilizers
- Corticosteroids
- Others
- Global Allergic Conjunctivitis Market, By Disease Type :
- Mild Allergic Conjunctivitis
- Severe Allergic Conjunctivitis
- Global Allergic Conjunctivitis Market, By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Allergic Conjunctivitis Market, By Region:
- North America
- By Drug Class
- Antihistamines & Mast Cell Stabilizers
- Corticosteroids
- Others
- By Disease Type
- Mild Allergic Conjunctivitis
- Severe Allergic Conjunctivitis
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Drug Class
- Antihistamines & Mast Cell Stabilizers
- Corticosteroids
- Others
- By Disease Type
- Mild Allergic Conjunctivitis
- Severe Allergic Conjunctivitis
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class
- Antihistamines & Mast Cell Stabilizers
- Corticosteroids
- Others
- By Disease Type
- Mild Allergic Conjunctivitis
- Severe Allergic Conjunctivitis
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class
- Antihistamines & Mast Cell Stabilizers
- Corticosteroids
- Others
- By Disease Type
- Mild Allergic Conjunctivitis
- Severe Allergic Conjunctivitis
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class
- Antihistamines & Mast Cell Stabilizers
- Corticosteroids
- Others
- By Disease Type
- Mild Allergic Conjunctivitis
- Severe Allergic Conjunctivitis
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class
- Antihistamines & Mast Cell Stabilizers
- Corticosteroids
- Others
- By Disease Type
- Mild Allergic Conjunctivitis
- Severe Allergic Conjunctivitis
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Eton Pharmaceutical *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Novartis AG
- Bausch & Lomb Incorporated
- Allergan
- Ocular Therapeutix, Inc.
- Eyevance Pharmaceuticals LLC
- Alcon
- Santen Pharmaceutical Co., Ltd
- Auven Therapeutics
- Atopix Therapeutics Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
